| Code | CSB-RA011087MB7HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to VB-421, targeting the insulin-like growth factor 1 receptor (IGF1R). IGF1R is a transmembrane tyrosine kinase receptor that plays a critical role in cell growth, proliferation, differentiation, and survival through activation of PI3K/AKT and MAPK signaling pathways. Upon binding IGF-1 or IGF-2, IGF1R undergoes autophosphorylation and initiates downstream cascades that regulate cellular metabolism and prevent apoptosis. Dysregulated IGF1R signaling is implicated in various malignancies, including colorectal, breast, lung, and prostate cancers, where it contributes to tumor growth, metastasis, and resistance to conventional therapies.
VB-421 is an investigational therapeutic antibody designed to inhibit IGF1R signaling in cancer cells. This biosimilar provides researchers with a valuable tool for studying IGF1R-mediated oncogenic pathways, investigating mechanisms of therapeutic resistance, and exploring combination treatment strategies in preclinical cancer models. The antibody enables detailed examination of IGF1R's role in tumor biology and metabolic regulation across diverse experimental systems.
There are currently no reviews for this product.